A Cancer Therapeutic Vaccine based on Clustered Tn‐Antigen Mimetics Induces Strong Antibody‐Mediated Protective Immunity1. (28th August 2014)

• Record Type: Journal Article
• Authors: Richichi, Barbara; Thomas, Baptiste; Fiore, Michele; Bosco, Rosa; Qureshi, Huma; Nativi, Cristina; Renaudet, Olivier; BenMohamed, Lbachir
• Is Part Of: Angewandte Chemie. Volume 126:Number 44(2014)
• Page Start: 12111
• Page End: 12114
• Publication Date: 2014-08-28
• Subjects: Chemistry -- Periodicals; 540
• DOI: 10.1002/ange.201406897
• Languages: English
• ISSNs: 0044-8249

Abstract

<abstract abstract-type="main" xml:lang="en"> <title>Abstract</title> <p>Tumor‐associated carbohydrate antigens (TACAs) are key components of cancer vaccines. A variety of vaccines based on native TACAs such as α‐Tn have shown immunogenicity and protection in preclinical animal studies, however, their weak immunogenicity, low in vivo instability, and poor bioavailability, have discouraged their further evaluations in clinical studies. A new improved vaccine prototype is reported. It is composed of four clustered Tn‐antigen mimetics and a immunogenic peptide epitope that are conjugated to a cyclopeptide carrier. The immunization of mice with this vaccine 1) was safe, 2) induced a strong and long‐lasting Tn‐specific response with IgM/IgG antibodies able to recognize native carbohydrate antigens; 3) produced high titers of IgG1, IgG2a, and IgG3 antibodies; and 4) produced a significant antibody‐dependent regression of tumors and conferred protection. Altogether, these findings pave the way for the clinical development of safe and effective therapeutic vaccines against Tn‐expressing cancers.</p> </abstract>